Abstract 1447P
Background
Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- radiation +/- immune checkpoint inhibitors (ICI) may benefit from a second-line CT mostly based on paclitaxel and irinotecan but no randomized trial compared these regimens.
Methods
OESIRI-PRODIGE 62 is a multicenter, open-label, randomized phase II trial evaluating efficacy and safety of nanoliposomal irinotecan (Nal-IRI) + 5FU versus paclitaxel as second-line CT in mESCC. The primary endpoint was percentage of pts alive at 9 months (OS) (H0=40% and H1=60%). With α 5%, power 85% and 5% of pts lost to follow-up, 53 pts per arm (n=106) were required. Secondary endpoints were progression-free survival (PFS), overall response rate (ORR), safety and quality of life (QoL).
Results
Between March 2019 and July 2023, 106 pts were randomized. Median age was 65.6 years, 83.0% men and 29.2%/58.5%/12.3% ECOG PS 0/1/2. Most pts had lymph node (68.3%), lung (52.9%) and liver metastases (24.8%). As prior treatment, 48.6% had chemoradiation, 41.9% CT alone and 9.5% CT plus ICI. The OS rate at 9 months was 34.0% [90%CI: 22.9-46.5] and 39.2% [90%CI: 27.7-51.7] in 5FU Nal-IRI and paclitaxel arms, respectively. Primary endpoint was not met. Median PFS were 2.4 [95%CI: 2.1-3.6] and 2.1 [95%CI: 1.9-3.3] months, disease control rates 47.8% and 40.4%, and median OS 7.1 [95%CI: 5.2-8.3] and 6.6 [95%CI: 4.8-10.3] months, respectively. 51.0% and 38.5% of pts experienced at least one grade 3-4 adverse events related to the treatment (neuropathy: 2.0 vs 7.7%, leucopenia: 6.1 vs 15.4%, diarrhea: 16.3% vs 0% and vomiting: 10.2 vs 0%), in 5FU Nal-IRI and paclitaxel arms, respectively. Two toxic deaths were observed in 5FU Nal-IRI arm. Treatment stop and dose reduction for toxicity were observed in 10.4% versus 3.9%, and 77.8% versus 83.3% in 5FU Nal-IRI and paclitaxel arms, respectively. 63.0% and 48.3% had a deterioration in QoL (loss of more than 5 points of the EORTC-QLQC30).
Conclusions
OESIRI-PRODIGE 62 trial showed low efficacy of paclitaxel and 5FU Nal-IRI in 2nd line treatment for mESCC patients, though paclitaxel provided better safety profile.
Clinical trial identification
NCT03719924.
Editorial acknowledgement
Legal entity responsible for the study
Fédération Francophone de Cancérologie Digestive.
Funding
Servier.
Disclosure
D. Tougeron: Financial Interests, Personal, Advisory Board: AstraZeneca, Sanofi, Amgen, MSD, Roche, Servier, Pierre Fabre, BMS, Bayer; Non-Financial Interests, Member of Board of Directors: Federation Francophone de Cancerologie Digestive. C. Poisson Ligeza: Financial Interests, Personal, Invited Speaker: Servier. V. Bourgeois: Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Principal Investigator: AstraZeneca; Non-Financial Interests, Personal, Non financial benefits, Congress Invitation: Merck, Amgen, Viatris, Pierre Fabre, MSD. V. Jestin: Financial Interests, Personal, Other, invitation à une formation: Novartis, MSD, Merck; Financial Interests, Personal, Other, contribution organisation réunion scientifique: Leopharma; Financial Interests, Personal, Invited Speaker: Sanofi. O. Dubreuil: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Sanofi, Pierre Fabre, Servier, MSD, AstraZeneca. O. Bouche: Financial Interests, Personal, Advisory Board: Amgen, Merck, Apmonia Therapeutics, Deciphera, Astellas, Takeda; Financial Interests, Personal, Invited Speaker: Servier, Pierre Fabre, Bayer. A. Lievre: Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, BMS, Esteve, Pierre Fabre Oncologie, Servier, Viatris; Financial Interests, Personal, Advisory Board: Astellas, BMS, Bayer, Servier; Financial Interests, Institutional, Research Grant, RePERSO trial: Bayer; Financial Interests, Institutional, Coordinating PI, SOCRATE trial (FFCD promotion): Lilly; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Bayer, Incyte, Lilly; Non-Financial Interests, Other, Travel and meeting registration: Bayer, Pierre Fabre, Servier, Viatris. F. Di Fiore: Financial Interests, Personal, Advisory Board: Amgen, BMS; Financial Interests, Personal, Invited Speaker: AstraZeneca, Sanofi, Bayer, Ipsen, Merck, Roche, Servier, MSD, Pierre Fabre, Takeda, Janssen. T. Lecomte: Financial Interests, Personal, Advisory Board: Sanofi, Merck Serono, Servier, Amgen, Ipsen, Pierre Fabre, AstraZeneca, Deciphera, Bayer. C. Lepage: Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Invited Speaker: Amgen, Pierre Fabre, Ipsen. V. Hautefeuille: Financial Interests, Personal, Invited Speaker: Novartis, Merck, Amgen; Financial Interests, Personal, Advisory Board: AAA, Ipsen, Pierre Fabre; Financial Interests, Institutional, Invited Speaker: Deciphera, Esteve. All other authors have declared no conflicts of interest.
Resources from the same session
1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Presenter: Anton Lahusen
Session: Poster session 18
1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients
Presenter: Tingting You
Session: Poster session 18
1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer
Presenter: Marie-Edith Bonneterre
Session: Poster session 18
1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes
Presenter: Laura Gutierrez Sainz
Session: Poster session 18
1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy
Presenter: Sai Surendran
Session: Poster session 18
1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy
Presenter: Steffen Ormanns
Session: Poster session 18
1512P - The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer
Presenter: Keita Sonoda
Session: Poster session 18
1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)
Presenter: Omali Pitiyarachchi
Session: Poster session 18
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18